Evaxion (EVAX) Q3 2026 Earnings Call Transcript
Runway stretches to 2027 as oncology vaccine focus sharpens.
Evaxion (EVAX) held its Q3 2026 earnings call, focusing on a strategic refocus on its AI-Immunology platform for oncology programs. The company reported an extended cash runway until the end of 2027, achieved through disciplined resource allocation and at-the-market equity sales. Clinical validation for Evaxion's platform was showcased through three-year phase II data for the EVX-01 vaccine, which demonstrated high target precision and durable immune responses in metastatic melanoma.
Moving forward, Evaxion plans to concentrate its resources in three key areas: furthering the development of off-the-shelf cancer vaccines EVX-04 and EVX-05, expanding the potential of EVX-01 beyond advanced melanoma, and identifying new antigens and indications through deeper analysis of the dark genome with AI-Immunology. The company's pipeline will focus solely on oncology assets, while preclinical assets in infectious disease and autoimmune disease will be pursued through partnerships.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.